Bavarian Nordic A/S (OTCMKTS:BVNRY) Short Interest Update

Bavarian Nordic A/S (OTCMKTS:BVNRY) was the recipient of a large decrease in short interest in January. As of January 31st, there was short interest totalling 3,400 shares, a decrease of 76.7% from the January 15th total of 14,600 shares. Based on an average daily trading volume, of 14,800 shares, the short-interest ratio is presently 0.2 days.

Bavarian Nordic A/S Stock Performance

Shares of Bavarian Nordic A/S stock traded down $0.10 on Wednesday, reaching $7.88. 5,459 shares of the company’s stock were exchanged, compared to its average volume of 9,338. Bavarian Nordic A/S has a 52 week low of $6.86 and a 52 week high of $14.60. The firm’s 50-day moving average is $8.88 and its two-hundred day moving average is $10.09. The company has a market capitalization of $1.86 billion, a P/E ratio of 11.42 and a beta of 1.68.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.